Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 640-454-2 | CAS number: 17318-08-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral LD50 (rat): 2000 mg/kg bw < LD50 < 5000 mg/kg bw (GLP, OECD TG 425)
Dermal LD50 (rat) >5000 mg/kg bw (GLP, OECD TG 402)
Inhalation LC50 (rat) >5.36 mg/L (GLP, OECD TG 403)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Remarks:
- The study was conducted to meet the national regulatory requirements in a non-EEA country.
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Version / remarks:
- 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- up-and-down procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: SAGE® Labs
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 164-210 grams
- Fasting period before study: overnight
- Housing: Animals were group housed, except on the day of administration, at which time they were single housed and until the animals were deemed acceptable, based on observations, to return to group housing
- Diet (e.g. ad libitum): Envigo Teklad Global 16% Protein Rodent Diet #2016 ad libitum (except for pre-dose fast)
- Water (e.g. ad libitum): Filtered tap water ad libitum
- Acclimation period: 6-25 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-23
- Humidity (%): 51-77
- Air changes (per hr): 12 or 13
- Photoperiod (hrs dark / hrs light): 12-hour light/dark cycle
IN-LIFE DATES: Start: June 5, 2018; End: July 19, 2018 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- In an acute oral toxicity study, a group of fasted,
8-12 weeks old, female, Sprague-Dawley derived, albino rats were given a single oral dose of CA5528. Prior to dosing, the rats were fasted overnight. During the fasting period, the rats were examined for health and weighed. Individual doses were calculated based on the initial body weights, taking into account the density of the test substance. - Doses:
- 5000 mg/kg or 2000 mg/kg
- No. of animals per sex per dose:
- Four at 5000 mg/kg; five at 2000 mg/kg
- Control animals:
- no
- Details on study design:
- The animals were observed for mortality, signs of gross toxicity, and behavioural changes within the first several hours post-dosing and at least once daily thereafter for up to 14 days after dosing or until death occurred. Observations included gross evaluation of skin and fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous systems, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhea and coma.
Individual body weights of the animals were recorded prior to test substance administration (initial day 0) and again on days 7 and 14 (termination) following dosing or after death.
One rat was euthanized for humane reasons due to test substance exposure. Surviving rats were euthanized on Day 14. All animals were euthanized via CO2 inhalation. Gross necropsies were performed on all deceased and euthanized animals. Tissues and organs of the thoracic and abdominal cavities were examined. - Statistics:
- Statistical analysis was limited to the calculation of the mean density value for dosing.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 - < 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Three of four animals receiving 5000 mg/kg died, whereas there was no mortality at 2000 mg/kg.
- Clinical signs:
- other: 5000 mg/kg dose level (4 animals): Two females died within six days of test substance administration. One animal was euthanized for humane reasons on Day 3. Prior to death, all animals were hypoactive and exhibited irregular respiration, nasal discharge
- Gross pathology:
- 5000 mg/kg dose level (4 animals): Gross necropsy of the deceased animals revealed distention of the intestines and/or stomach. No gross abnormalities were noted for the animal euthanized for humane reasons on Day 3. No gross abnormalities were noted for the surviving animal when necropsied at the conclusion of the 14-day observation period.
2000 mg/kg dose level (5 animals): No gross abnormalities were noted for any of the animals when necropsied at the conclusion of the 14-day observation period. - Interpretation of results:
- Category 5 based on GHS criteria
- Conclusions:
- Under the conditions of this study, the acute oral median lethal dose (LD50) of CA5528 is between 2000 mg/kg and 5000 mg/kg of body weight in female rats.
- Executive summary:
The acute oral toxicity test was conducted with rats to determine the potential for CA5528 - (Composition: CA5528, 99.8% w/w) to produce toxicity from a single dose via the oral route.
An initial limit dose of 5000 mg/kg of body weight was administered to one healthy female rat by oral gavage. Due to the absence of mortality in this animal, two additional females received the same dose level, simultaneously. Since both animals died, one additional animal was tested. Due to the mortality in this animal, the study proceeded to a limit test at 2000 mg/kg of body weight at the request of the Sponsor. An initial limit dose of 2000 mg/kg was administered to one healthy rat by oral gavage. Due to the absence of mortality in this animal, four additional females received the same dose level, sequentially. Since these animals survived, no additional animals were tested. Females were selected for the test because they are frequently more sensitive to the toxicity of test compounds than males.
The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs at approximately 30-60 minutes, 1 and approximately 3 hours after treatment on day 1 and once daily during test days 2 to 14 or until death. Body weights were recorded on day 1 (prior to test substance administration) and on days 7 and 14 or after death. All animals were examined macroscopically.
Of the 4 animals administered a limit dose of 5000 mg/kg, two females died within six days of test substance administration. One animal was euthanized for humane reasons on Day 3. Prior to death, all animals were hypoactive and exhibited irregular respiration, nasal discharge, reduced fecal volume, ocular discharge, piloerection, soft feces, prone posture and/or was moribund. One animal survived the limit dose of 5000 mg/kg. Following administration, the surviving animal was hypoactive and exhibited irregular respiration, abnormal gait, facial staining, ocular discharge, hunched posture, abdominal distention and ano-genital staining. However, the animal recovered by Day 6 and appeared active and for the remainder of the 14-day observation period, gaining body weight over the course of the study. Gross necropsy of the deceased animals revealed distention of the intestines and/or stomach.
At 2000 mg/kg dose level (5 animals), all animals survived exposure to the test substance and gained body weight. Following administration, two animals were hypoactive and four animals exhibited irregular respiration, facial staining, reduced fecal volume, oral discharge ano-genital staining and/or were cold to the touch. However, these animals recovered by Day 6 and appeared active and healthy for the remainder of the study. One animal did not exhibit any signs of toxicity.
The body weight of the surviving animals was within the range commonly recorded for this strain and age.
No macroscopic findings were recorded for the survivors at necropsy.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Quality of whole database:
- A fully reliable and valid study according to relevant OECD test guidelines and GLP is available.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Remarks:
- The study was conducted to meet the national regulatory requirements in a non-EEA country.
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- 2009
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: SAGE® Labs USA
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 10-11 weeks
- Weight at study initiation: 332-396 g (males), 210-240 g (females)
- Fasting period before study: no
- Housing: The animals were housed in caging which conforms to the size recommendations in the most recent Guide for the Care and Use of Laboratory Animals (Natl. Res. Council, 2011). Animals were group housed, except on the day of exposure, at which time they were singly housed and until the animals were deemed acceptable, based on observations, to return to group housing.
- Diet (e.g. ad libitum): Envigo Teklad Global 16% Protein Rodent Diet #2016 ad libitum (except during exposure)
- Water (e.g. ad libitum): Filtered tap water ad libitum (except during exposure)
- Acclimation period: 19 or 23 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-23
- Humidity (%): 50-77
- Air changes (per hr): 12 or 13
- Photoperiod (hrs dark / hrs light): 12 hours light / 12 hours dark
IN-LIFE DATES: Start: June 8, 2018; End: July 9, 2018 - Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Mass median aerodynamic diameter (MMAD):
- 3.68 µm
- Geometric standard deviation (GSD):
- 2.4
- Remark on MMAD/GSD:
- MMAD was measured at 1.5 and 3 hours into exposure, and measured values were 3.94 and 3.41 µm, respectively. Geometric standard deviation was 2.44 and 2.33.
- Details on inhalation exposure:
- Exposure conditions: Prior to initiation of the full inhalation study, pre-test trials were conducted to establish generation procedures to achieve, to the extent possible, the desired chamber and desired particle size distribution (mass median aerodynamic diameter between
1 and 4 μm). Exposure conditions during the study are given later in a table of the test atmosphere characteristics of CA5528.
Generation of the test atmosphere/chamber description: A nose-only inhalation chamber was used for exposure. Animals were individually housed in polycarbonate holding tubes which seal to the chamber with an “O” ring during exposure. The base unit terminates the chamber with a 0.5-inch diameter tube for discharged air.
Air Supply: Filtered generator air was supplied to the spray atomization nozzle by an air compressor, and measured with a Mass Flow Controller. Additional filtered mixing air from the same air compressor, measured with a Mass Flow Controller, was introduced into the chamber to help uniformly distribute the test atmosphere by creating a vortex at the chamber inlet. Chamber airflow was monitored throughout the exposure period and recorded periodically. The exposure was conducted under slight negative pressure.
Ambient Conditions: The temperature and relative humidity within the exposure chamber as well as the room were monitored continuously during exposure, and were measured with a temperature-humidity monitor. Temperature and relative humidity values were recorded every 15 minutes for the first hour of exposure and approximately every 15 or 30 minutes thereafter.
Atmosphere Generation: The test atmosphere was generated using a nebulizer. The test substance was metered to the atomization nozzle through PharMed® BPT tubing, using a peristaltic pump. - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 4 h
- Remarks on duration:
- The animals were exposed to the targeted chamber concentration for at least 4 hours. The exposure period was extended beyond 4 hours to allow the chamber to reach equilibrium (T99).
- Concentrations:
- 5.36 mg/L
- No. of animals per sex per dose:
- Five
- Control animals:
- no
- Details on study design:
- Fourteen healthy, naive rats not previously tested were selected for exposure. Two males and two females were selected for the sighting test at 5.0 mg/L and five males and five females were selected for the main test at 5.0 mg/L. Prior to the start of the study they were examined to ensure that they were physically normal and exhibited normal activity. All animals were observed for mortality during the exposure period. The animals were examined for signs of gross toxicity, and behavioural changes upon removal from the exposure tube and at least once daily thereafter for 14 days or until death. Observations included gross evaluation of skin and fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous systems, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhea and coma. The body weight of each rat was recorded prior to exposure and on days 1, 3, 7 and 14.
All rats were euthanized via CO2 inhalation at the end of the 14-day observation period. Gross necropsies were performed on all animals. Tissues and organs of the thoracic and abdominal cavities were examined. - Statistics:
- Statistical analysis was limited to the calculation of the mean and standard deviation. Since no death occurred at the limit dose, the LC50 was determined without the need of statistical analysis.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 5.36 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- There were no mortalities at a concentration of 5.37 mg/L and there were no mortalities at a concentration of 5.36 mg/L.
- Clinical signs:
- other: All animals exhibited irregular respiration and/or ano-genital staining. However, all animals recovered by Day 3 and appeared active and healthy for the remainder of the study.
- Body weight:
- All animals gained body weight during the study.
- Gross pathology:
- Apart from discoloration of the lungs in one male and one female, there were no other gross abnormalities noted for any animal when necropsied at the conclusion of the 14-day observation period.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the experimental conditions of this study, the acute inhalation median lethal concentration (LC50) of CA5528 is greater than 5.36 mg/L in Sprague-Dawley derived, albino male and female rats.
- Executive summary:
In an acute inhalation toxicity study, groups of young adult Sprague-Dawley-derived, albino rats (5/sex/group) were exposed via the inhalation (nose-only exposure) route to CA5528. Test atmospheres were analyzed for particulate concentration.
After establishing the desired generation procedures during the pre-test trials, fourteen healthy rats were selected for test. A sighting test with an initial exposure level of 5.0 mg/L was selected for testing using two animals per sex (2 males and 2 females). Since all male and female rats survived the sighting test, an additional five animals per sex (5 males and 5 females) were selected for the main test with a 5.0 mg/L exposure level. Chamber concentration and particle size distributions of the test atmosphere were determined periodically during the exposure period. The animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days following exposure. Body weights were recorded prior to exposure (initial) and again on Days 1, 3, 7, and 14 (terminal). Necropsies were performed on all animals at terminal sacrifice.
The achieved test atmosphere had the following characteristics:
Sighting study (5 mg/L): 5.37 ± 0.29 mg/L achieved, MMAD: 2.97; 3.22 µm, GSD: 2.45; 2.45
Main study (5 mg/L): 5.36 ± 0.48 mg/L achevied, MMAD: 3.94; 3.41 µm, GSD: 2.44; 2.33
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- A fully reliable and valid study according to relevant OECD test guidelines and GLP is available.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Remarks:
- The study was conducted to meet the national regulatory requirements in a non-EEA country.
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 2017
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: SAGE® Labs
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: Young adult (10-12 weeks)
- Weight at study initiation: males 334-376 grams and females 210-239 grams
- Fasting period before study: no
- Housing: Animals were group housed, except on the day of application, at which time they were singly housed until the animals were deemed acceptable, based on observations, to return to group housing.
- Diet (e.g. ad libitum): Envigo Teklad Global 16% Protein Rodent Diet #2016 ad libitum
- Water (e.g. ad libitum): Filtered tap water ad libitum
- Acclimation period: 21 or 29 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-23
- Humidity (%): 52-77
- Air changes (per hr): 12 or 13
- Photoperiod (hrs dark / hrs light): 12-hour light/dark cycle
IN-LIFE DATES: Start: June 14, 2018; End: July 11, 2018 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- Initial testing was conducted on one male and one female rat to determine extreme clinical signs or severe irritation potential of the test substance. Due to the absence of clinical signs or severe local signs of irritation, an additional four males and four females were tested. Five thousand milligrams of the test substance per kilogram of body weight was applied evenly over a dose area of approximately 2 inches x 3 inches (approximately 10% of the body surface) and covered with a 2-inch x 3-inch, 4-ply gauze pad. The gauze pad and entire trunk of each animal were then wrapped with 3-inch Durapore tape to avoid dislocation of the pad and to minimize loss of the test substance. The rats were then returned to their designated cages. The day of application was considered Day 0 of the study.
After 24 hours of exposure to the test substance, the pads were removed and the test sites were gently cleansed with a 3% soap solution followed by tap water and a paper towel to remove any residual test substance. - Duration of exposure:
- 24 hours
- Doses:
- 5000 mg/kg bw (Individual doses were calculated based on the initial body weights, taking into account the density of the test substance)
- No. of animals per sex per dose:
- Five (initial test was done with one animal per sex)
- Control animals:
- no
- Details on study design:
- The animals were observed for mortality, signs of gross toxicity, and behavioural changes during the first several hours after application and at least once daily thereafter for 14 days. Observations included gross evaluation of skin and fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous systems, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhea and coma.
Individual body weights of the animals were recorded prior to test substance application (initial) and again on day 7 and day 14 (terminal).
All surviving rats were killed by CO2 inhalation at the end of the 14-day observation period.
Gross necropsies were performed on all animals killed at the end of the study. Tissues and organs of the thoracic and abdominal cavities were examined. - Statistics:
- Statistical analysis was limited to the calculation of the mean density value for dosing. Since no deaths occurred at the limit dose, the LD50 was determined without the need of statistical analysis.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred
- Clinical signs:
- other: All animals survived test substance administration during the study. Other than the dermal irritation noted at the dose site of all animals between Days 1 and 8, there were no other adverse clinical findings recorded for any animal over the course of the
- Gross pathology:
- No gross abnormalities were noted for any of the animals when necropsied at the conclusion of the 14-day observation period.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this study, the single dose acute dermal median lethal dose (LD50) of CA5528 is greater than 5000 mg/kg of body weight in male and female rats.
- Executive summary:
An acute dermal toxicity test was conducted with rats to determine the potential for CA5528 to produce toxicity from a single topical application. Initially, 5000 mg/kg of the test substance was applied to the skin of one healthy male rat and one healthy female rat for 24 hours. Due to the absence of clinical signs or severe local signs of irritation, an additional four males and four females were tested. The animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days. Body weights were recorded prior to application (initial), on Day 7, and on Day 14 (terminal). Necropsies were performed on all animals.
All animals survived test substance administration and gained body weight during the study. Other than the dermal irritation noted at the dose site of all animals between Days 1 and 8, there were no other adverse clinical findings recorded for any animal over the course of the study. No gross abnormalities were noted for any of the animals when necropsied at the conclusion of the 14-day observation period.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- A fully reliable and valid study according to relevant OECD test guidelines and GLP is available.
Additional information
Justification for classification or non-classification
The substance does not meet the criteria for classification for acute toxicity in accordance with CLP-Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.